Prospecção Científica e Tecnológica acerca da Covid-19: análise das abordagens terapêuticas farmacológicas inseridas no contexto pandêmico
DOI:
https://doi.org/10.9771/cp.v13i2.36194Palavras-chave:
Hidroxicloroquina, Coronavírus, TratamentoResumo
O SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) é um vírus com alta capacidade de disseminação que pode causar uma forte pneumonia. Como ainda não há um tratamento efetivo recomendado pela Organização Mundial de Saúde (OMS), o presente estudo realizou uma prospecção científica e tecnológica, destacando possíveis tratamentos que possam ser eficazes no combate à Covid-19. A coleta de artigos e de patentes sobre o SARS-CoV-2 foi realizada por meio de palavras-chave nos bancos Web of Science, SciELO (Scientific Electronic Library Online), PubMed (Public MEDLINE) e Scopus e nas bases de patentes World Intellectual Property Organization (WIPO), United States Patent and Trademark Office (USPTO), Instituto Nacional de Propriedade Industrial (INPI) e European Patent Office (EPO). Na prospecção, foram contabilizados 81 artigos acerca do tratamento e nenhuma patente depositada nos bancos supracitados, evidenciando forte procura para o tratamento, apesar de não apresentar registro de patentes para o produto ou para o processo.
Downloads
Referências
ASHOUR, H. M. et al. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens, v. 9, n. 3, p. 1–15, 2020. DOI: 10.3390/pathogens9030186.
BARON, S. A. et al. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? International Journal of Antimicrobial Agents, [S.l.], p. 1-6, 2020. DOI:10.1016/j.ijantimicag.2020.105944.
CAO, B. et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. New England Journal of Medicine, [S.l.], p. 1-13, 2020a. DOI: 10.1056/NEJMoa2001282.
CAO, J. et al. Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China. Clinical Infectious Diseases, [S.l.], 2020b. DOI:10.1093/cid/ciaa243.
CHEN, E. Q. et al. Brief report of the first cured 2019-nCoV pneumonia patient in West China Hospital. European Journal of Clinical Microbiology & Infectious Diseases, [S.l.], p. 1-3, 2020a. DOI: 10.1007/s10096-020-03866-z.
CHEN, Q. et al. A report of clinical diagnosis and treatment of 9 cases of coronavirus disease 2019. Journal of medical virology, [S.l.], p.1-5, 2020b. DOI:10.1002/jmv.25755.
CHEN, Y. W.; YIU, C. B.; WONG, K. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000 Research, [S.l.], v. 9, 2020. DOI:10.12688/f1000research.22457.1
CUI, Y. et al. A 55-Day-Old Female Infant infected with COVID 19: presenting with pneumonia, liver injury, and heart damage. The Journal of Infectious Diseases, [S.l.], p. 1-7, 2020. DOI:10.1093/infdis/jiaa113.
DENG, S. Q.; PENG, H. J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. Journal of Clinical Medicine, [S.l.], v. 9, n. 2, p. 575, 2020.
DROSTEN, C. et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. New England journal of medicine, [S.l.], v. 348, n. 20, p. 1.967-1.976, 2003.
ELFIKY, A. A. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sciences, [S.l.], p. 117477, 2020a. DOI:10.1016/j.lfs.2020.117477.
ELFIKY, A. A. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sciences, [S.l.], p. 117.592, 2020b. DOI: 10.1016/j.lfs.2020.117592.
FAN, H. et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model. Chinese Medical Journal, [S.l.], 2020. DOI: 10.1097/CM9.0000000000000797.
FU, Y.; CHENG, Y.; WU, Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virologica Sinica, [S.l.], v. 12.250, 2020. DOI: 10.1007/s12250-020-00207-4.
GAUTRET, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, [S.l.], p. 1-25, 2020. DOI:10.1016/j.ijantimicag.2020.105949.
GAO, J.; TIAN, Z.; YANG, X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends, [S.l.], 2020. DOI:10.5582/bst.2020.01047.
GRALINSKI, L. E.; MENACHERY, V. D. Return of the Coronavirus: 2019-nCoV. Viruses, [S.l.], v. 12, n. 2, p. 135, 2020.
HOFFMANN, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell, [S.l.], p. 1-10, 2020. DOI: 10.1016/j.cell.2020.02.052.
HUANG, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, [S.l.], v. 395, n. 10.223, p. 497-506, 2020.
INCIARDI, R. M. et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology, [S.l.], 2020. DOI: 10.1001/jamacardio.2020.1096
KHALILI, J. S. et al. Novel coronavirus treatment with ribavirin: Groundwork for evaluation concerning COVID-19. Journal of Medical Virology, [S.l.], 2020. DOI:10.1002/jmv.25798.
KHAN, S. A. et al. Identification of Chymotrypsin-like Protease Inhibitors of SARS-CoV-2 Via Integrated Computational Approach. Journal of Biomolecular Structure and Dynamics, [S.l.], 2020. DOI: 10.1080/07391102.2020.1751298
LAI, C. C. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. International Journal of Antimicrobial Agents, [S.l.], v. 55, n. 3, p. 105924, 2020.
LAUER, S. A. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine, [S.l.], 2020. DOI: 10.7326/M20-0504.
LIAN, J. et al. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clinical Infectious Diseases, [S.l.], 2020. DOI:10.1093/cid/ciaa242.
LIM, J. et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean Medical Science, [S.l.], v. 35, n. 6, p. 1-6, 2020.
LING, Y. et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chinese Medical Journal, [S.l.], 2020. DOI: 10.1097/CM9.0000000000000774.
LIU, F. et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. International Journal of Infectious Diseases, [S.l.], 2020a. DOI: 10.1016/j.ijid.2020.03.013.
LIU, J. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, [S.l.], v. 6, n. 1, p. 1-4, 2020b.
LIU, Y. et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences, [S.l.], v. 63, n. 3, p. 364-374, 2020c.
LIU, W. et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal, [S.l.], 2020d. DOI: 10.1097/CM9.0000000000000775.
LIU, S.; ZHENG, Q.; WANG, Z. Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus. Bioinformatics, [S.l.], 2020. DOI: 10.1093/bioinformatics/btaa224.
LUNG, J. et al. The potential chemical structure of anti‐SARS‐CoV‐2 RNA‐dependent RNA polymerase. Journal of Medical Virology, [S.l.], 2020. DOI:10.1002/jmv.25761.
NI, L. et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan. Frontiers of Medicine, [S.l.], p. 1-5, 2020. DOI: 10.1007/s11684-020-0757-x.
ORTEGA, J. et al. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target. EXCLI Journal, [S.l.], v. 19, p. 400, 2020. DOI: 10.17179/excli2020-1189.
QUINTELLA, C. M.; MATA, A. M. T.; GHESTI, G. F. Vacinas para Coronavírus (COVID-19; SARS- COV-2): mapeamento preliminar de artigos, patentes, testes clínicos e mercado. Cadernos de Prospecção, Salvador, v. 13, n. 1, p. 3-12, março, 2020. DOI: 10.9771/cp.v13i1.35871.
ROBSON, B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Computers in Biology and Medicine, [S.l.], p. 103670, 2020. DOI: 10.1016/j.compbiomed.2020.103670.
RUNFENG, L. Lianhuaqingwen exerts anti-viral and anti-inflammatory activityagainst novel coronavirus (SARS-CoV-2). Pharmacological Research, [S.l.], v. 104.761, 2020. DOI: 10.1016/j.phrs.2020.104761.
SHANMUGARAJ, B. et al. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pacific Journal of Allergy and Immunology, [S.l.], v. 38, n. 1, p. 10-18, 2020. DOI: 10.12932/AP-200220-0773.
SUN, D. et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study. World Journal of Pediatrics, [S.l.], 2020. DOI: 10.1007/s12519-020-00354-4.
TAI, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular & Molecular Immunology, [S.l.], p. 1-8, 2020. DOI: 10.1038/s41423-020-0400-4.
WAN, S. et al. Clinical Features and Treatment of COVID‐19 Patients in Northeast Chongqing. Journal of Medical Virology, [S.l.], p. 1-10, 2020. DOI:10.1002/jmv.25783.
WANG, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama, [S.l.], 2020a. DOI: 10.1001/jama.2020.1585.
WANG, Z. et al. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clinical Infectious Diseases, [S.l.], p. 1-27, 2020b. DOI: 10.1093/cid/ciaa272.
WANG, Z. et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Bioscience Trends, [S.l.], p. 1-5, 2020c. DOI: 10.5582/bst.2020.01030.
WHO – WORLD HEALTH ORGANIZATION. Coronavirus disease (COVID-19) Situation dashboard. 2020. Disponível em: https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd. Acesso em: 2 abr. 2020.
WIT, E. et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proceedings of the National Academy of Sciences, [S.l.], v. 117, n. 12, p. 6.771-6.776, 2020.
WU, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Medicine, [S.l.], 2020. DOI:10.1001/jamainternmed.2020.0994.
WU, D.; YANG, X. O. Th17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. Journal of Microbiology, Immunology and Infection, [S.l.], 2020. DOI:10.1016/j.jmii.2020.03.005.
XU, K. et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang da xue xue bao. Yi xue ban= Journal of Zhejiang University. Medical sciences, [S.l.], v. 49, n. 1, p. 0-0, 2020. DOI: 10.3785/j.issn.1008-9292.2020.02.02.
YAO, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, [S.l.], p. 1-25, 2020. DOI:10.1093/cid/ciaa237.
YETHINDRA, V. Role of GS-5734 (Remdesivir) in inhibiting SARS-CoV and MERS-CoV: The expected role of GS-5734 (Remdesivir) in COVID-19 (2019-nCoV)-VYTR hypothesis. International Journal of Research in Pharmaceutical Sciences, [S.l.], v.11 (SPL1), p. 1-6, 2020. DOI:10.26452/ijrps.v11iSPL1.1973.
YANG, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine, [S.l.], 2020. DOI:10.1016/S2213-2600(20)30079-5.
YOUNG, B. E. et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. Jama, [S.l.], 2020. DOI: 10.1001/jama.2020.3204.
YUAN, J. et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflammation Research, [S.l.], p. 1-8, 2020. DOI:10.1007/s00011-020-01342-0.
ZHANG, D. et al. In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus. Journal of Integrative Medicine, [S.l.], v. 18, n. 2, p. 152-158, 2020.
ZHONG, N. S. et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. The Lancet, [S.l.], v. 362, n. 9393, p. 1.353-1.358, 2003.
ZHOU, D.; DAI, S. M.; TONG, Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. Journal of Antimicrobial Chemotherapy, [S.l.], p. 1-4, 2020a. DOI:10.1093/jac/dkaa114.
ZHOU, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery, [S.l.], v. 6, n. 1, p. 1-18, 2020b. DOI: 10.1038/s41421-020-0153-3.
ZHU, L. et al. Successful recovery of COVID‐19 pneumonia in a renal transplant recipient with long‐term immunosuppression. American Journal of Transplantation, [S.l.], p. 1-6, 2020. DOI:10.1111/ajt.15869.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Copyright (c) 2020 Cadernos de Prospecção
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos.
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.
